The article presents the author's views on study on the risk of relapse of endometrial hyperplasia in pregnancy, published in this issue. He comments that the type of hormonal therapy used to treat the endometrial hyperplasia are linked with the relapse risk. HE opines that for treatment of non-atypical endometrial hyperplasia, the Local intrauterine progestogen (LNG)-IUS is preferred.